NCT04971226 · OUTCOME
Change From Baseline in EORTC QLQ-CML24 Scales at Week 48 and Week 96
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP · Source last updated 2026-08-28
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- Baseline, week 48 and week 96.
What was measured
The QLQ-CML24 consists of multi-scale items: symptom burden, impact on worry/mood, impact on daily life, body image problems, satisfaction with care and information and satisfaction with social life.
A higher score on most of the item scales in QLQ-CML24 reflects a larger impairment in the corresponding domain, with the exception of the satisfaction with care and information, and problems and satisfaction with social life, where a higher score reflects a higher level of satisfaction.
Analysis population: Full Analysis Set: All participants who had an EORTC QLQ-CML24 assessment both at baseline and at week 48.
Groups in this outcome
Asciminib (All Asciminib)
Patients took asciminib 80 mg QD under fasting conditions on ongoing basis.
Investigator Selected TKI (All Comparators)
Patients will take on ongoing basis the Investigator selected TKIs (imatinib, nilotinib, dasatinib or bosutinib)
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
| Group | Source count |
|---|
| Asciminib (All Asciminib) | 77 |
|---|
| Investigator Selected TKI (All Comparators) | 66 |
|---|
Reported measurements
Symptom Burden
Very much better
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 2 | Not reported | Not reported | Not reported | Not reported |
|---|
Moderately better
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 12 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 4 | Not reported | Not reported | Not reported | Not reported |
|---|
A little better
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 18 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 5 | Not reported | Not reported | Not reported | Not reported |
|---|
Unchanged
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 27 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 22 | Not reported | Not reported | Not reported | Not reported |
|---|
A little worse
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 7 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 16 | Not reported | Not reported | Not reported | Not reported |
|---|
Moderately worse
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 6 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 12 | Not reported | Not reported | Not reported | Not reported |
|---|
Very much worse
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 7 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 5 | Not reported | Not reported | Not reported | Not reported |
|---|
Impact on Worry/Mood
Very much better
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 11 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 7 | Not reported | Not reported | Not reported | Not reported |
|---|
Moderately better
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 7 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 9 | Not reported | Not reported | Not reported | Not reported |
|---|
A little better
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 20 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 6 | Not reported | Not reported | Not reported | Not reported |
|---|
Unchanged
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 17 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 18 | Not reported | Not reported | Not reported | Not reported |
|---|
A little worse
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 16 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 11 | Not reported | Not reported | Not reported | Not reported |
|---|
Moderately worse
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 2 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 4 | Not reported | Not reported | Not reported | Not reported |
|---|
Very much worse
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 4 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 11 | Not reported | Not reported | Not reported | Not reported |
|---|
Impact on Daily Life
Very much better
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 21 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 17 | Not reported | Not reported | Not reported | Not reported |
|---|
Moderately better
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 26 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 10 | Not reported | Not reported | Not reported | Not reported |
|---|
A little better
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Unchanged
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 19 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 23 | Not reported | Not reported | Not reported | Not reported |
|---|
A little worse
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Moderately worse
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 6 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 5 | Not reported | Not reported | Not reported | Not reported |
|---|
Very much worse
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 5 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 11 | Not reported | Not reported | Not reported | Not reported |
|---|
Body Image Problems
Very much better
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 18 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 10 | Not reported | Not reported | Not reported | Not reported |
|---|
Moderately better
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
A little better
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Unchanged
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 48 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 41 | Not reported | Not reported | Not reported | Not reported |
|---|
A little worse
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Moderately worse
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Very much worse
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 11 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 15 | Not reported | Not reported | Not reported | Not reported |
|---|
Satisfaction with Care and Information
Very much better
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 8 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 13 | Not reported | Not reported | Not reported | Not reported |
|---|
Moderately better
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 5 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 4 | Not reported | Not reported | Not reported | Not reported |
|---|
A little better
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Unchanged
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 30 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 31 | Not reported | Not reported | Not reported | Not reported |
|---|
A little worse
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Moderately worse
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 18 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 7 | Not reported | Not reported | Not reported | Not reported |
|---|
Very much worse
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 16 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 11 | Not reported | Not reported | Not reported | Not reported |
|---|
Satisfaction with Social Life
Very much better
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 15 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 14 | Not reported | Not reported | Not reported | Not reported |
|---|
Moderately better
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
A little better
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Unchanged
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 40 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 37 | Not reported | Not reported | Not reported | Not reported |
|---|
A little worse
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Moderately worse
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Very much worse
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Asciminib (All Asciminib) | 22 | Not reported | Not reported | Not reported | Not reported |
|---|
| Investigator Selected TKI (All Comparators) | 15 | Not reported | Not reported | Not reported | Not reported |
|---|
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 2
- title
- Very much better
- measurements
- group Id
- OG000
- value
- 12
- group Id
- OG001
- value
- 4
- title
- Moderately better
- measurements
- group Id
- OG000
- value
- 18
- group Id
- OG001
- value
- 5
- title
- A little better
- measurements
- group Id
- OG000
- value
- 27
- group Id
- OG001
- value
- 22
- title
- Unchanged
- measurements
- group Id
- OG000
- value
- 7
- group Id
- OG001
- value
- 16
- title
- A little worse
- measurements
- group Id
- OG000
- value
- 6
- group Id
- OG001
- value
- 12
- title
- Moderately worse
- measurements
- group Id
- OG000
- value
- 7
- group Id
- OG001
- value
- 5
- title
- Very much worse
- title
- Symptom Burden
- categories
- measurements
- group Id
- OG000
- value
- 11
- group Id
- OG001
- value
- 7
- title
- Very much better
- measurements
- group Id
- OG000
- value
- 7
- group Id
- OG001
- value
- 9
- title
- Moderately better
- measurements
- group Id
- OG000
- value
- 20
- group Id
- OG001
- value
- 6
- title
- A little better
- measurements
- group Id
- OG000
- value
- 17
- group Id
- OG001
- value
- 18
- title
- Unchanged
- measurements
- group Id
- OG000
- value
- 16
- group Id
- OG001
- value
- 11
- title
- A little worse
- measurements
- group Id
- OG000
- value
- 2
- group Id
- OG001
- value
- 4
- title
- Moderately worse
- measurements
- group Id
- OG000
- value
- 4
- group Id
- OG001
- value
- 11
- title
- Very much worse
- title
- Impact on Worry/Mood
- categories
- measurements
- group Id
- OG000
- value
- 21
- group Id
- OG001
- value
- 17
- title
- Very much better
- measurements
- group Id
- OG000
- value
- 26
- group Id
- OG001
- value
- 10
- title
- Moderately better
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- title
- A little better
- measurements
- group Id
- OG000
- value
- 19
- group Id
- OG001
- value
- 23
- title
- Unchanged
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- title
- A little worse
- measurements
- group Id
- OG000
- value
- 6
- group Id
- OG001
- value
- 5
- title
- Moderately worse
- measurements
- group Id
- OG000
- value
- 5
- group Id
- OG001
- value
- 11
- title
- Very much worse
- title
- Impact on Daily Life
- categories
- measurements
- group Id
- OG000
- value
- 18
- group Id
- OG001
- value
- 10
- title
- Very much better
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- title
- Moderately better
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- title
- A little better
- measurements
- group Id
- OG000
- value
- 48
- group Id
- OG001
- value
- 41
- title
- Unchanged
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- title
- A little worse
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- title
- Moderately worse
- measurements
- group Id
- OG000
- value
- 11
- group Id
- OG001
- value
- 15
- title
- Very much worse
- title
- Body Image Problems
- categories
- measurements
- group Id
- OG000
- value
- 8
- group Id
- OG001
- value
- 13
- title
- Very much better
- measurements
- group Id
- OG000
- value
- 5
- group Id
- OG001
- value
- 4
- title
- Moderately better
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- title
- A little better
- measurements
- group Id
- OG000
- value
- 30
- group Id
- OG001
- value
- 31
- title
- Unchanged
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- title
- A little worse
- measurements
- group Id
- OG000
- value
- 18
- group Id
- OG001
- value
- 7
- title
- Moderately worse
- measurements
- group Id
- OG000
- value
- 16
- group Id
- OG001
- value
- 11
- title
- Very much worse
- title
- Satisfaction with Care and Information
- categories
- measurements
- group Id
- OG000
- value
- 15
- group Id
- OG001
- value
- 14
- title
- Very much better
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- title
- Moderately better
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- title
- A little better
- measurements
- group Id
- OG000
- value
- 40
- group Id
- OG001
- value
- 37
- title
- Unchanged
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- title
- A little worse
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- title
- Moderately worse
- measurements
- group Id
- OG000
- value
- 22
- group Id
- OG001
- value
- 15
- title
- Very much worse
- title
- Satisfaction with Social Life
- denoms
- counts
- group Id
- OG000
- value
- 77
- group Id
- OG001
- value
- 66
- units
- Participants
- description
- The QLQ-CML24 consists of multi-scale items: symptom burden, impact on worry/mood, impact on daily life, body image problems, satisfaction with care and information and satisfaction with social life.
A higher score on most of the item scales in QLQ-CML24 reflects a larger impairment in the corresponding domain, with the exception of the satisfaction with care and information, and problems and satisfaction with social life, where a higher score reflects a higher level of satisfaction.
- groups
- description
- Patients took asciminib 80 mg QD under fasting conditions on ongoing basis.
- id
- OG000
- title
- Asciminib (All Asciminib)
- description
- Patients will take on ongoing basis the Investigator selected TKIs (imatinib, nilotinib, dasatinib or bosutinib)
- id
- OG001
- title
- Investigator Selected TKI (All Comparators)
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- Full Analysis Set: All participants who had an EORTC QLQ-CML24 assessment both at baseline and at week 48.
- reporting Status
- POSTED
- time Frame
- Baseline, week 48 and week 96.
- title
- Change From Baseline in EORTC QLQ-CML24 Scales at Week 48 and Week 96
- type
- SECONDARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle